Teratinib, as a new generation ROS1 inhibitor, is a masterpiece of the medical community's precise efforts to address the important pathogenic mechanism of ROS1 gene rearrangement in lung cancer.
Advantages of Function
1. Dual targets: highly effective in inhibiting ROS1 and NTRK1-3;
2. Good safety, high response rate, long effective duration, and longer disease-free survival for patients;
3. It is also effective for ROS1 positive non-small cell lung cancer patients who have failed treatment with crizotinib (the main resistance site ROS1G2032R also has a highly effective inhibitory effect) and patients with brain metastases;
4. Unrestricted cancer types, it can be used with ROS1 or NTRK fusion mutations, making it a new generation of broad-spectrum anti-cancer drugs with the potential to compete with internationally leading star products Larotrectinib (LOXO-101), Entrectinib (RXDX-101), and under development products Repotrectinib (TPX-0005, riptinib).
adverse reaction
The most commonly reported adverse reactions (≥ 20%) are diarrhea, nausea, vomiting, dizziness, rash, constipation, and fatigue.
The most commonly reported level 3 or 4 laboratory abnormalities (≥ 5%) include: elevated ALT, elevated AST, decreased neutrophils, and elevated creatine phosphokinase.
Usage and Dosage
Select locally advanced or metastatic non-small cell lung cancer patients for treatment based on the presence of ROS1 gene rearrangement.
Recommended dosage: Take 600 milligrams orally once a day on an empty stomach (do not eat for at least 2 hours before or after taking IBTROZI).
Continue treatment until the disease progresses or unacceptable toxic reactions occur.
indication
The declared indication is for the treatment of ROS1 fusion positive non-small cell lung cancer (NSCLC) patients who have previously received ROS1-TKI therapy.
2. The proposed indication is for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are ROS1 positive and have not received ROS1-TKI therapy.
3. NTRK fusion solid tumor.
